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Abstract
Adequate intake of folate, methionine, riboflavin, and vitamin B-6 may prevent aberrant DNA methylation and thereby
protect against colorectal cancer (CRC). However, previous epidemiological studies investigating associations between
dietary intakes of these nutrients and CRC have been inconsistent. We investigated the associations between intakes of
folate, methionine, riboflavin, and vitamin B-6 and CRC risk, accounting for the sublocalization of the tumor. Within the
Netherlands Cohort Study on diet and cancer (n ¼ 120,852), 2349 cases and 4168 subcohort members were available for
data analyses from a follow-up period of 13.3 y after baseline. Gender-specific adjusted incidence rate ratios (RR) were
calculated over quintiles of dietary intake in case-cohort analyses. Folate intake was not associated with CRC risk in either
men or women. However, methionine was associated with decreased risk of proximal colon cancer among men (RR ¼
0.57 for highest vs. lowest quintile of intake; P-trend ¼ 0.03) and rectal cancer among women (highest vs. lowest quintile;
RR ¼ 0.45; P-trend ¼ 0.05). Riboflavin tended to be associated with decreased proximal colon cancer risk among women
(RR ¼ 0.61; P-trend ¼ 0.07). Conversely, there was a strong positive association between vitamin B-6 and rectal cancer
among women (RR ¼ 3.57; P-trend ¼ 0.01). Our findings suggest that relatively high methionine intake may protect
against proximal colon cancer in men and rectal cancer in women but that folate may not have a protective effect. This is
the 2nd prospective cohort study in which vitamin B-6 intake was associated with increased risk of rectal tumors in
women, which might suggest that this vitamin enhances rectal cancer in women. J. Nutr. 138: 2372–2378, 2008.
Introduction
It has been proposed that folate may affect colorectal carcino-
genesis because of its role in the synthesis of nucleic acid andDNA
methylation (1). Folate deficiency may result in uracil mis-
incorporation in DNA, which possibly leads to DNA instability
and gene alterations. It may also cause aberrant DNA methyl-
ation such as CpG island promoter hypermethylation or global
hypomethylation, which, in turn, may contribute to colorectal
carcinogenesis. For example, hypermethylation of gene pro-
moters is known to result in silencing of tumor suppressor genes
andDNArepair genes,which in turnmay enhance carcinogenesis
(2). Therefore, it may be hypothesized that adequate folate levels
possibly protect against colorectal cancer (CRC).7 However,
epidemiological studies on the relation between dietary folate
intake and CRC risk have not consistently shown a protective
effect of high folate intake (3,4). Also, it has been suggested that
the effect of folate supplementation may depend on the stage of
colorectal carcinogenesis, i.e. it would protect against carcino-
genesis in normal colorectal tissue but might enhance already
existing lesions (5,6). In this respect, the relation between dietary
folate and the etiology of CRC continues to be the subject of
debate.
Like folate, methionine is required for the synthesis of
S-adenosylmethionine, which is the universal methyl group
donor needed for methylation processes (7). Adequate intakes of
folate or methionine through the diet ensure a sufficient supply
of methyl groups and it may be hypothesized that this also
prevents aberrant DNA methylation. Other B-vitamins such as
riboflavin and vitamin B-6 are involved in the folate-mediated
1-carbon metabolism and may therefore modulate the bioavail-
ability of methyl groups. Riboflavin, as flavin adenine dinucle-
otide, is the cofactor for methylenetetrahydrofolate reductase
(MTHFR), the enzyme that influences homocysteine remethyla-
tion and DNA methylation. Low riboflavin status was previously
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observed to be associated with increased homocysteine concen-
tration, which possibly results in lower availability of methyl
groups (8). In addition, vitamin B-6 is involved in the conversion
of tetrahydrofolate into 5,10-methylenetetrahydrofolate, one of
the steps of the folate cycle (7). On the other hand, high alcohol
intake potentially reduces the bioavailability of folate and such a
disruption of the 1-carbon metabolism may affect DNA methyl-
ation in, for example, the colonic mucosa (9–11).
The associations between dietary intakes of riboflavin, vitamin
B-6, and methionine have been investigated in a number of
studies. However, whereas a potential protective effect of ribo-
flavin intake on colorectal adenomas was observed in 1 study
(12), others have not demonstrated an associationwith CRC at all
(13,14). Similarly, relatively high methionine intake did not seem
to protect against CRC (13,15–17). Several studies demonstrated
an inverse association between vitamin B-6 intake and CRC
(17–21), although in 1 study, the vitamin was positively associated
with rectal tumors among women (16). Theremay be a number of
reasons for these inconsistencies between studies, such as the
danger of selection bias and possibly recall bias that could have
played a larger role in case-control studies. In this respect, some
of the studies had a prospective cohort design (15,16,18–21),
whereas others were case-control studies (12–14,17). Moreover,
some studies were conducted among women only (15,16,19–21)
or in relation to colorectal adenomas (12) and there are consider-
able differences in the level of vitamin intake between studies.
The relation between folate and CRC is still controversial and
previous studies on associations between folate, B-vitamins, and
methionine with CRC have inconsistencies. This prompted us to
investigate the combination of folate, riboflavin, vitaminB-6, and
methionine in a prospective setting. The study was conducted
among incident CRC patients and subcohort members of the
Netherlands Cohort Study on diet and cancer (NLCS), which is a
largepopulation-basedstudywithaprospective case-cohortdesign.
Subjects and Methods
Study population. The participants in this study were incident colon
and rectal cancer patients and subcohort members from the NLCS,
which has been described in detail elsewhere (22). Briefly, the study was
initiated in September 1986 and included 58,279 men and 62,573
women aged 55–69 y at baseline, who originated from 204 Dutch
municipalities with computerized population registers. At baseline,
participants completed a self-administered FFQ that also provided
information about age, sex, and other risk factors for cancer. The entire
cohort is being monitored for cancer occurrence by annual record
linkage to the Netherlands Cancer Registry (9 cancer registries in The
Netherlands). Accumulation of person-time in the cohort has been
estimated through biennial follow-ups of vital status in a subcohort of
5000 men and women who were randomly selected after baseline
exposure measurement. Cases with prevalent cancer other than non-
melanoma skin cancer were excluded from this subcohort, which left
4774 men and women eligible for analysis. CRCwas classified according
to the International Classification of Diseases (ICD) as follows: colon,
i.e. proximal colon (ICD-O-1 codes 153.0, 153.1, 153.4, 153.5, 153.6)
and distal colon (153.2, 153.3, 153.7), rectosigmoid (154.0), rectum
(154.1), or ICD-O-1 codes 153.8 and 153.9 if information of the disease
site was not available. Follow-up information was available from a
follow-up period up to 13.3 y after baseline, i.e. from September 1986
until January 2000. Within this period, 2679 CRC patients were
identified.
FFQ. The self-administered questionnaire was a 150-item, semiquanti-
tative FFQ, which concentrated on habitual consumption of food and
beverages during the year preceding the start of the study and also
contained questions about body weight and length, smoking status,
physical activity, and family history of CRC. Daily mean nutrient intakes
were calculated as the cumulated product of the frequencies and portion
sizes of all food items and their tabulated nutrient contents from the
Dutch Food Composition Table (NEVO table, 1986) (23). The ques-
tionnaire was validated through comparison with a 9-d diet record (24)
and the reproducibility was determined (25). Questionnaire data were
key-entered twice for all incident cases in the cohort and for all
subcohort members in a blinded manner with respect to case/subcohort
status. This was done to minimize observer bias in coding and
interpretation of the data.
Folate data were derived from a validated liquid chromatography
trienzyme method (26) used to analyze the 125 most important Dutch
foods contributing to folate intake (27). Mean daily intakes of all other
relevant nutrients were calculated using the computerized Dutch Food
Composition Table (23). Dietary supplement data were also obtained via
the FFQ. However, the use of B-vitamin supplements was low (7%) and
folic acid was generally not included in these supplements in The
Netherlands in the late 1980s. Therefore, folic acid supplement use most
likely plays a very minor role in our study population and supplement
use was not further accounted for in the analyses.
Statistical analyses. Analyses were performed for all CRC cases
combined and for each sublocalization, i.e. proximal colon, distal colon,
rectosigmoid, and rectum. Dietary factors and other baseline character-
istics were evaluated for men and women separately for subcohort
members and CRC cases by calculating means and SD for continuous
variables and distributions of the categorical variables.
Cox proportional hazards regression models were used to estimate
gender-specific multivariate-adjusted incidence rate ratios (RR) and
corresponding 95% CI over quintiles of folate intake, methionine,
riboflavin, and vitamin B-6 using the lowest quintiles as reference.
Standard errors of the RR were estimated using the robust Huber-White
sandwich estimator to account for additional variance introduced by
sampling from the cohort (28). Tests for dose response trends over the
quintiles of intake were estimated by fitting the ordinal exposure
variables as continuous variables and evaluated using the Wald test. To
account for potentially nonlinear effects due to skewed distributions of
folate, methionine, riboflavin, and vitamin B-6, we also estimated the
associations between the quintile variables and CRC by replacing the
quintiles with the median intakes within each quintile and compared
those RR with the main analyses. The proportional hazards assumption
was tested using the scaled Schoenfeld residuals (29) and by fitting the
main determinants as time-dependent variables. Analyses were addi-
tionally stratified for the first and 2nd half of the follow-up time. Because
undetected preclinical disease may have affected exposure status, we
excluded the first year of follow-up in additional subanalyses and
compared these results with the analyses performed over the full 13.3 y
of follow-up. In addition to gender-specific analyses, we also conducted
overall analyses for men and women combined.
The dietary variables were adjusted for total energy intake by
calculating nutrient residuals from the regression of nutrient intake on
total energy intake, as described by Willett et al. (30). Such nutrient
residuals are uncorrelated with total energy intake and the effect of the
variation in nutrient intake can subsequently be estimated independently
of a potential effect of energy intake. Tests for heterogeneity were
performed to evaluate differences between sublocalizations of tumors
using the competing risks procedure in Stata. However, the standard
error for the difference of the log hazard ratio from this procedure
assumes independence of both estimated hazard ratios, which would
underestimate that SE and thus overestimate the P-values for their
difference. Therefore, these P-values and the associated CI were
estimated based on a bootstrapping method that was developed for the
case-cohort design (31). For each bootstrap sample, X subcohort
members were randomly drawn from the subcohort of X subjects and
Y cases from the total of Y cases outside the subcohort, both with
replacement, out of the dataset of X 1 Y observations. The log hazard
ratios were obtained from this sample using Stata’s competing risks
procedure and recalculated for each bootstrap replication. The CI and
P-value of the differences in hazard ratio of the subtypes were then
calculated from the replicated statistics. Each bootstrap analysis was
based on 1000 replications.
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First, we estimated the individual associations of dietary folate,
methionine, riboflavin, and vitamin B-6 with CRC in separate models.
However, because the bioavailability of methyl groups donated by folate
and methionine may be influenced by riboflavin and vitamin B-6, the
effects of these nutrients may not be independent and should then be
mutually adjusted for. There were no major differences between the
associations of these individual models compared with the multivariate
analysis including folate, methionine, riboflavin, and vitamin B-6
simultaneously, and these main determinants were therefore included
simultaneously in all further analyses.
The covariates considered as potential confounders were suggested
risk factors of CRC and those commonly included as confounders in
observational studies on the associations of B-vitamins and CRC (12–21).
Covariates were includedwhen they substantially influenced the RR of any
of the main determinants folate, methionine, riboflavin or vitamin B-6.
This applied to the variables BMI, smoking status, energy, calcium and
meat (RR of any of the main determinants changed by more than 5%
when adding each of these variables separately) and alcohol, iron, fat, fiber
(RR of main determinants changed even more than 10%). The variables
age and having a family history of CRC may be strong determinants for
CRC and were therefore included as well.
We also conducted analyses using models only including the 4 main
determinants and the variable age and compared the results of these
crude results to the multivariate-adjusted analyses. After excluding sub-
jects with missing information on these covariates or those who did not
complete the questionnaire, 4168 subcohort members and 2349 CRC
cases remained for statistical analyses.
We determined possible interactions between dietary intakes of fo-
late, methionine, riboflavin, vitamin B-6, and alcohol intake. This was
done by first testing, in separate models, the gender-specific interaction
terms between folate on the one hand, with methionine, riboflavin, vita-
min B-6, and alcohol on the other, for all CRC tumors combined and for
each of the 4 sublocalizations. The Cox proportional hazard analyses
without the interaction terms were subsequently stratified by low or high
intake of folate, methionine, riboflavin, and vitamin B-6 using the me-
dian intakes as cut-off values to define both strata within each variable.
The strata used for alcohol intake were abstainers, subjects with intake
,30 g/d, and subjects who consumed $30 g/d.
All statistical analyses were performed with the Stata statistical
software package (version 9.1).
Results
During a period of 13.3 y of follow-up, 1389 men and 960
women with CRC were identified who also had complete in-
formation on the covariates used in the adjusted regression
analyses. The mean intakes of the main determinants folate,
methionine, riboflavin, and vitamin B-6 were generally similar
between subcohort members and cases in most of the subgroups
among both men and women (Table 1). Only the intakes of
folate among men with a distal colon tumor and of riboflavin
among women with a tumor in the rectosigmoid appeared
slightly lower compared with subcohort members. The percent-
ages of subjects with a family history of CRC were generally
higher in cases than in subcohort members. The other variables
did not differ between subcohort members and CRC patients.
We subsequently estimated multivariate-adjusted incident
RR over quintiles of folate intake, methionine, riboflavin, and
vitamin B-6 for men and women.
TABLE 1 Baseline dietary intake and other characteristics of subcohort members and cancer cases from the NLCS1
Men Women
Subcohort
All
tumors
Proximal
colon
Distal
colon Rectosigmoid Rectum Subcohort
All
tumors
Proximal
colon
Distal
colon Rectosigmoid Rectum
Patient characteristics
n2 2090 1389 382 467 141 360 2078 960 386 296 78 176
Age, y 61.3 6 4.2 62.0 6 4.1 62.5 6 4.0 62.0 6 4.2 62.0 6 3.9 61.6 6 4.0 61.4 6 4.3 62.6 6 4.0 62.9 6 4.0 62.1 6 4.1 62.8 6 3.6 62.4 6 3.8
Family history of
CRC, % yes
5.4 9.3 10.0 9.4 10.6 8.1 6.0 9.8 10.9 9.1 7.7 9.1
BMI, kg/m2 24.9 6 2.6 25.2 6 2.6 25.1 6 2.6 25.4 6 2.8 25.6 6 2.6 25.1 6 2.5 25.0 6 3.5 25.1 6 3.5 25.3 6 3.5 25.0 6 3.4 25.1 6 3.2 25.0 6 3.6
Smoking status, %
Never 12.8 11.0 11.5 12.0 9.9 9.4 57.6 59.8 61.4 62.1 51.3 58.5
Ex-smoker 52.6 59.9 57.3 64.5 58.2 57.5 20.8 21.2 20.7 21.0 28.2 19.3
Current smoker 35.6 29.1 31.1 23.5 31.9 33.1 21.6 19.0 17.9 16.9 20.5 22.2
Dietary factors
Folate, mg/d 224.6 6 66.6 222.1 6 65.0 222.0 6 68.1 217.4 6 54.1 227.7 6 80.5 225.9 6 65.7 198.5 6 61.1 199.1 6 61.3 196.4 6 58.2 199.4 6 62.4 196.5 6 51.7 204.8 6 67.7
Methionine, mg/d 1713 6 293 1701 6 277 1696 6 280 1697 6 2.70 1714 6 287 1710 6 2.71 1489 6 276 1482 6 278 1474 6 2.98 1483 6 251 1450 6 250 1512 6 279
Riboflavin, mg/d 1.58 6 0.37 1.55 6 0.34 1.56 6 0.35 1.54 6 0.32 1.56 6 0.34 1.55 6 0.34 1.45 6 0.34 1.43 6 0.35 1.43 6 0.35 1.46 6 0.34 1.33 6 0.30 1.48 6 0.37
Vitamin B-6, mg/d 1.54 6 0.27 1.55 6 0.27 1.54 6 0.27 1.53 6 0.27 1.55 6 0.25 1.57 6 0.29 1.33 6 0.24 1.33 6 0.24 1.33 6 0.25 1.32 6 0.23 1.33 6 0.21 1.36 6 0.25
Alcohol, %
0 g/d 14.6 12.4 12.0 14.5 9.9 11.1 32.3 33.8 34.7 33.8 29.5 34.1
,30 g/d 70.6 69.7 74.6 67.5 73.8 67.2 64.1 61.4 59.8 61.8 61.1 63.1
$30 g/d 14.8 17.9 13.4 18.0 16.3 21.7 3.6 4.8 5.5 4.4 6.4 2.8
Energy, kJ/d 9080 6 2134 8949 6 2059 8923 6 2006 8846 6 2135 8841 6 1946 9149 6 2008 7062 6 1659 6980 6 1608 6994 6 1698 6933 6 1541 7071 6 1944 6991 6 1332
Meat, g/d 137 6 52 136 6 49.7 134 6 49 136 6 49 137 6 53 137 6 50 116 6 46 115 6 45 112 6 46 115 6 42 123 6 40 117 6 47
Fat, g/d 93.9 6 14.2 94.0 6 13.6 95.0 6 12.4 94.8 6 14.0 93.7 6 14.3 92.2 6 14.1 74.0 6 10.3 74.1 6 10.3 73.6 6 10.8 74.5 6 10.0 75.4 6 8.6 74.0 6 10.3
Fiber, g/d 28.7 6 7.3 28.8 6 7.0 28.6 6 7.1 28.4 6 6.6 28.9 6 6.9 29.4 6 7.1 25.3 6 5.8 25.1 6 5.9 25.2 6 6.2 24.9 6 5.5 24.8 6 6.0 25.4 6 5.8
Calcium, mg/d 948 6 295 932 6 281 947 6 286 919 6 267 932 6 2.96 944 6 287 901 6 268 896 6 274 898 6 2.93 909 6 2.54 804 6 218 913 6 2.81
Iron, mg/d 13.3 6 2.4 13.3 6 2.4 13.2 6 2.26 13.3 6 2.3 13.5 6 2.5 13.5 6 2.4 11.7 6 2.0 11.6 6 1.9 11.6 6 2.0 11.5 6 1.9 11.6 6 1.8 11.8 6 1.9
Vitamin C, mg/d 98.6 6 41.6 99.7 6 40.6 98.8 6 40.5 96.7 6 38.6 99.5 6 40.3 103.1 6 42.6 108.4 6 42.7 109.3 6 45.5 108.0 6 46.1 109.9 6 44.4 110.4 6 36.5 109.5 6 48.4
Fruits, g/d 155 6 114 160 6 112 158 6 107 158 6 107 161 6 121 166 6 120 197 6 121 195 6 83 194 6 134 195 6 117 201 6 98 191 6 123
Vegetables, g/d 191 6 85 192 6 86 191 6 91 185 6 76 192 6 73 205 6 95 196 6 82 194 6 83 193 6 83 191 6 77 206 6 85 200 6 88
1 Values are mean 6 SD or percentages if indicated otherwise.
2 Numbers of subcohort members and patients are based on complete availability of the variables presented in this table. Information about the tumor localization was unavailable
for 39 men and 22 women.
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After 13.3 y of follow-up, folate intake was not significantly
associated with risk of CRC at any of the subsites in men (Table
2) or women (Table 3). Among men, methionine was associated
with a decreased risk of proximal colon cancer (RR¼ 0.57; CI¼
0.28–1.18; P-trend ¼ 0.03), whereas among women, it was
inversely associated with rectal cancer (RR ¼ 0.45; CI ¼ 0.17–
1.20; P-trend ¼ 0.05). Among women, riboflavin tended to be
inversely associated with proximal colon cancer (RR for the
highest vs. the lowest quintile of intake ¼ 0.61; CI ¼ 0.35–1.06;
P-trend ¼ 0.07). Conversely, there was a strong positive asso-
ciation between vitamin B-6 and rectal cancer risk in women
(RR ¼ 3.57; CI ¼ 1.56–8.17; P-trend ¼ 0.01). An increased RR
for vitamin B-6 could also be observed for all CRC tumors
combined among women, although this risk was not as high and
was not significant (RR ¼ 1.39; CI ¼ 0.92–2.08; P-trend ¼
0.09). When performing the analyses for men and women to-
gether, the highest quintile of vitamin B-6 intake was also
positively associated with overall CRC (RR ¼ 1.34; CI ¼ 1.03–
1.74; P-trend ¼ 0.02), with proximal colon cancer (RR ¼ 1.37;
CI ¼ 0.93–2.01; P-trend ¼ 0.05) and rectal cancer (RR ¼ 1.86;
CI ¼ 1.17–2.95; P-trend ¼ 0.02, data not shown).
Adjustment for potential confounders only slightly aggra-
vated the estimated associations compared with age-adjusted
analyses but did not result in different conclusions (Tables 2
and 3). There were no significant interactions between folate,
methionine, riboflavin, or vitamin B-6 and alcohol intake for
overall CRC or for the individual sublocalizations. In addition,
we did not observe consistent differences when comparing the
RR between strata of low or high intakes of folate, methionine,
riboflavin, and vitamin B-6 or alcohol (data not shown).
Although the adjusted models did not meet the proportional
hazards assumption according to the Schoenfeld residuals, fit-
ting the main determinants as time-dependent variables showed
that there was no interaction with time for these variables.
Furthermore, when stratifying the analysis based on follow-up
time, e.g. on the first and 2nd half of the follow-up period, we
observed no consistent differences compared with analyses on
the total follow-up period. This also applied to the results when
excluding the first year of follow-up. Estimating the relative risks
with the median intake within quintiles only slightly changed the
P-values for dose-response trends and did not result in different
conclusions. The tests for heterogeneity for the effects over the 4
subgroups of tumors were not significant.
Discussion
We investigated the associations between intakes of folate,
methionine, riboflavin, and vitamin B-6 with CRC risk. Our
TABLE 2 Associations between dietary folate, methionine, riboflavin, and vitamin B-6 with CRC risk in men
All tumors Proximal colon Distal colon Rectosigmoid Rectum
Quintile1 PY2 n3 RR (95% CI)4 RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5
Folate, mg/d
1 (160.8) 4840 292 1.00 1.00 77 1.00 111 1.00 29 1.00 65 1.00
2 (189.5) 4971 289 0.93 (0.74–1.17) 0.90 (0.71–1.13) 94 1.14 (0.80–1.61) 88 0.69 (0.50–0.97) 22 0.67 (0.37–1.22) 76 1.05 (0.72–1.55)
3 (212.1) 4848 271 0.88 (0.70–1.13) 0.85 (0.66–1.09) 61 0.77 (0.51–1.16) 94 0.72 (0.50–1.04) 37 1.18 (0.67–2.08) 74 1.03 (0.68–1.55)
4 (240.6) 4822 270 0.89 (0.69–1.14) 0.86 (0.66–1.11) 80 1.02 (0.68–1.51) 88 0.69 (0.47–1.01) 25 0.78 (0.40–1.50) 70 1.00 (0.64–1.56)
5 (297.2) 4829 267 0.93 (0.71–1.20) 0.87 (0.65–1.15) 70 0.97 (0.62–1.52) 86 0.71 (0.46–1.08) 28 0.83 (0.41–1.66) 75 1.01 (0.64–1.60)
P-trend6 0.43 0.29 0.65 0.16 0.72 0.92
Methionine, mg/d
1 (1366) 4960 296 1.00 1.00 77 1.00 104 1.00 31 1.00 72 1.00
2 (1555) 4805 284 1.01 (0.80–1.28) 0.96 (0.74–1.26) 91 1.07 (0.70–1.64) 86 0.91 (0.62–1.33) 26 0.83 (0.43–1.58) 71 1.03 (0.66–1.60)
3 (1698) 4971 277 0.96 (0.75–1.22) 0.87 (0.64–1.17) 83 0.87 (0.54–1.41) 91 0.89 (0.58–1.37) 30 0.81 (0.37–1.74) 68 0.98 (0.60–1.61)
4 (1843) 4803 282 0.98 (0.77–1.27) 0.90 (0.63–1.26) 65 0.65 (0.37–1.14) 105 1.13 (0.69–1.87) 26 0.65 (0.28–1.50) 79 1.21 (0.69–2.11)
5 (2093) 4772 250 0.91 (0.68–1.22) 0.79 (0.50–1.25) 66 0.57 (0.28–1.18) 81 1.03 (0.52–2.04) 28 0.65 (0.22–1.93) 70 1.09 (0.53–2.24)
P-trend 0.47 0.36 0.03 0.58 0.34 0.53
Riboflavin, mg/d
1 (1.17) 4944 315 1.00 1.00 82 1.00 93 1.00 35 1.00 89 1.00
2 (1.38) 4968 265 0.82 (0.66–1.03) 0.83 (0.65–1.05) 72 0.82 (0.56–1.20) 94 1.13 (0.80–1.60) 27 0.68 (0.38–1.20) 64 0.67 (0.45–0.99)
3 (1.53) 4815 284 0.91 (0.72–1.15) 0.92 (0.71–1.19) 78 0.91 (0.61–1.35) 108 1.44 (0.98–2.11) 22 0.56 (0.29–1.08) 71 0.73 (0.48–1.11)
4 (1.71) 4681 270 0.90 (0.70–1.16) 0.93 (0.69–1.24) 75 0.96 (0.60–1.52) 98 1.47 (0.95–2.29) 28 0.74 (0.38–1.43) 64 0.65 (0.40–1.03)
5 (2.03) 4903 255 0.83 (0.63–1.08) 0.86 (0.60–1.22) 75 0.91 (0.53–1.58) 74 1.22 (0.71–2.08) 29 0.72 (0.30–1.74) 72 0.66 (0.38–1.14)
P-trend 0.37 0.72 0.92 0.19 0.52 0.16
Vitamin B-6, mg/d
1 (1.22) 4838 257 1.00 1.00 70 1.00 94 1.00 25 1.00 59 1.00
2 (1.40) 4766 272 1.12 (0.89–1.40) 1.12 (0.87–1.43) 77 1.17 (0.80–1.71) 93 1.01 (0.71–1.45) 26 1.09 (0.59–2.04) 69 1.22 (0.81–1.82)
3 (1.53) 4959 283 1.14 (0.89–1.45) 1.13 (0.86–1.49) 82 1.23 (0.81–1.87) 93 0.98 (0.66–1.45) 26 1.09 (0.55–2.18) 78 1.32 (0.84–2.07)
4 (1.67) 4884 302 1.27 (0.99–1.63) 1.30 (0.97–1.75) 76 1.29 (0.81–2.06) 103 1.17 (0.76–1.79) 37 1.62 (0.78–3.36) 76 1.31 (0.81–2.12)
5 (1.88) 4863 275 1.18 (0.90–1.56) 1.29 (0.90–1.84) 77 1.50 (0.86–2.62) 84 1.03 (0.60–1.76) 27 1.28 (0.51–3.24) 78 1.35 (0.76–2.41)
P-trend 0.14 0.12 0.14 0.87 0.32 0.31
1 Quintile (median intake within quintile).
2 Number of accumulated person years (PY) within quintiles of dietary intake.
3 Number of cases.
4 Unadjusted incidence RR from a regression model including the variables folate, methionine, riboflavin, vitamin B-6, and age.
5 Adjusted RR from a regression model including the variables folate, methionine, riboflavin, vitamin B-6, age, family history of CRC, BMI, smoking status, and the intakes of
alcohol, energy, meat, fat, fiber, calcium, and iron.
6 P-value for linear trend over quintiles of intake.
B-vitamins and colorectal cancer risk 2375
 at Universiteit M
aastricht UB Randwijck - Verwerking on January 15, 2009 
jn.nutrition.org
D
ow
nloaded from
 
results do not suggest an association between dietary folate and
CRC. However, relatively high methionine intake was inversely
associated with proximal colon cancer in men and rectal cancer
in women. Also, a modest nonsignificant inverse association was
observed between riboflavin intake and tumors of the proximal
colon in women. Conversely, vitamin B-6 intake was positively
associated with overall CRC, which was particularly strong for
rectal cancer among women.
Previous observational studies did not consistently point to a
clear inverse association between folate intake and CRC risk.
Next to different sample sizes in those studies, this inconsistency
may also have been caused by possible selection bias that is likely
to occur in case-control studies but not in cohort studies, po-
tential differences in the level of over- or underestimation of
dietary intake using FFQ, and different adjustments for con-
founding factors between studies (3). In addition, the inconsis-
tencies may be due to differences between study populations and
inherent variation in levels of folate intake. The intake in our
study was relatively low, with the median folate intake within
quintiles ranging from 160 to 299 mg/d among men and 137 to
270 mg/d among women. However, among subjects with consid-
erably higher levels of intake studied in prospective cohort
settings, an inverse association was observed only twice (32,33),
whereas 3 other studies did not suggest this (15,16,34). More-
over, a significant inverse association was observed in a cohort
study among men with even lower intakes compared with men
in our study (compared highest and lowest category .249 vs.
,103 mg/d) (35), indicating that high ranges of intake do not
necessarily lead to reduced CRC risk. Nevertheless, in several
studies, the protective effect of folate was confined to either men
or women or limited to a specific study population or subsite of
CRC, which makes it difficult to generalize the results and hence
to be conclusive about whether dietary folate has a chemo-
preventive effect on CRC.
Despite the current view of the importance of folate in cancer
prevention, its role in colorectal carcinogenesis is still a subject
of debate. Interestingly, it was recently observed that high
plasma folate levels may be associated with increased CRC risk
(36) and possibly with breast cancer (37). An alternative hy-
pothesis in this regard is that although folate supplementation
may protect against the occurrence of neoplasia in normal
colorectal epithelium, it might promote already-existing early
lesions into cancer, suggesting that the effect depends on the
timing of intervention (5). It was also reported that folic acid
supplementation was associated with increased risk of advanced
lesions or recurrence of multiple adenomas after a follow-up of
3–5 y (38). Interestingly, the participants in that intervention
study were people with a recent history of colorectal adenomas,
TABLE 3 Associations between dietary folate, methionine, riboflavin, and vitamin B-6 with CRC risk in women
All tumors Proximal colon Distal colon Rectosigmoid Rectum
Quintile1 PY2 n3 RR (95% CI)4 RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5 n RR (95% CI)5
Folate, mg/d
1 (139.0) 5097 198 1.00 1.00 89 1.00 56 1.00 16 1.00 32 1.00
2 (165.6) 5121 185 0.96 (0.75–1.25) 0.98 (0.75–1.28) 66 0.79 (0.54–1.15) 65 1.19 (0.79–1.80) 15 1.13 (0.48–2.66) 34 1.03 (0.60–1.77)
3 (187.5) 5313 180 0.90 (0.69–1.18) 0.95 (0.71–1.27) 71 0.83 (0.55–1.24) 59 1.11 (0.70–1.75) 14 1.06 (0.42–2.66) 31 0.90 (0.49–1.65)
4 (212.9) 5156 200 1.11 (0.84–1.46) 1.17 (0.87–1.58) 79 1.07 (0.71–1.63) 59 1.21 (0.76–1.94) 19 1.62 (0.67–3.94) 40 1.18 (0.65–2.14)
5 (267.3) 5119 197 1.12 (0.82–1.52) 1.25 (0.89–1.76) 81 1.24 (0.76–2.02) 57 1.34 (0.81–2.22) 14 1.38 (0.51–3.75) 39 1.06 (0.53–2.11)
P-trend6 0.31 0.10 0.17 0.37 0.28 0.73
Methionine, mg/d
1 (1154) 5183 206 1.00 1.00 86 1.00 59 1.00 17 1.00 38 1.00
2 (1351) 5130 214 1.07 (0.84–1.38) 1.02 (0.76–1.36) 87 1.20 (0.80–1.82) 67 0.92 (0.59–1.45) 18 1.38 (0.61–3.15) 36 0.77 (0.43–1.38)
3 (1476) 5081 164 0.83 (0.63–1.10) 0.78 (0.56–1.10) 68 1.01 (0.62–1.65) 53 0.72 (0.42–1.22) 13 1.18 (0.43–3.24) 29 0.54 (0.27–1.05)
4 (1617) 5257 194 0.96 (0.73–1.28) 0.87 (0.59–1.29) 74 1.09 (0.61–1.92) 66 0.80 (0.44–1.45) 17 1.77 (0.56–5.56) 33 0.51 (0.24–1.08)
5 (1841) 5155 182 0.88 (0.65–1.21) 0.76 (0.46–1.26) 71 1.07 (0.51–2.22) 51 0.53 (0.24–1.19) 13 1.91 (0.52–6.92) 40 0.45 (0.17–1.20)
P-trend 0.30 0.18 0.86 0.16 0.31 0.05
Riboflavin, mg/d
1 (1.04) 5124 211 1.00 1.00 99 1.00 51 1.00 25 1.00 33 1.00
2 (1.26) 5067 194 0.91 (0.71–1.17) 0.89 (0.68–1.17) 79 0.74 (0.51–1.06) 57 1.12 (0.71–1.77) 17 0.81 (0.40–1.65) 35 0.99 (0.57–1.72)
3 (1.42) 5130 188 0.92 (0.71–1.19) 0.92 (0.69–1.23) 62 0.62 (0.41–0.93) 73 1.53 (0.95–2.46) 12 0.65 (0.28–1.51) 34 0.99 (0.55–1.79)
4 (1.59) 5294 187 0.85 (0.65–1.11) 0.84 (0.60–1.16) 71 0.61 (0.38–0.96) 60 1.24 (0.72–2.12) 16 0.86 (0.35–2.07) 34 0.91 (0.47–1.74)
5 (1.89) 5190 180 0.85 (0.63–1.14) 0.79 (0.53–1.18) 75 0.61 (0.35–1.06) 55 1.22 (0.62–2.40) 8 0.55 (0.15–2.03) 40 0.92 (0.41–2.04)
P-trend 0.26 0.30 0.07 0.40 0.47 0.76
Vitamin B-6, mg/d
1 (1.05) 5018 198 1.00 1.00 82 1.00 65 1.00 17 1.00 27 1.00
2 (1.21) 5278 189 0.98 (0.76–1.26) 1.04 (0.78–1.37) 75 1.02 (0.69–1.51) 61 0.90 (0.58–1.38) 10 0.67 (0.26–1.73) 38 1.73 (0.97–3.08)
3 (1.32) 5187 178 1.01 (0.75–1.34) 1.11 (0.80–1.52) 73 1.17 (0.75–1.82) 53 0.84 (0.50–1.39) 16 1.16 (0.43–3.11) 32 1.79 (0.91–3.54)
4 (1.44) 5324 194 1.08 (0.81–1.44) 1.23 (0.88–1.73) 85 1.35 (0.84–2.15) 60 0.97 (0.57–1.65) 18 1.31 (0.48–3.54) 28 1.73 (0.83–3.58)
5 (1.63) 4998 201 1.12 (0.81–1.55) 1.39 (0.92–2.08) 71 1.15 (0.65–2.04) 57 1.06 (0.56–2.03) 17 1.34 (0.38–4.64) 51 3.57 (1.56–8.17)
P-trend 0.42 0.09 0.33 0.86 0.36 0.01
1 Quintile (median intake within quintile).
2 Number of accumulated person years (PY) within quintiles of dietary intake.
3 Number of cases.
4 Unadjusted incidence RR from a regression model including the variables folate, methionine, riboflavin, vitamin B-6, and age.
5 Adjusted RR from a regression model including the variables folate, methionine, riboflavin, vitamin B-6, age, family history of colorectal cancer, BMI, smoking status, and the
intakes of alcohol, energy, meat, fat, fiber, calcium, and iron.
6 P-value for linear trend over quintiles of intake.
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and, possibly, undetected neoplasms were present in these sub-
jects, which may have had a growth advantage in the presence of
high concentrations of folic acid. Furthermore, after the intro-
duction of nationwide fortification of cereals with folic acid in
the United States and Canada, CRC incidence increased in these
countries, which may possibly be due to increased intakes folic
acid (39). A potentially harmful effect of folate may also be
confined to specific subgroups of cancers based on their mo-
lecular characteristics. In this respect, we previously observed
positive associations between folate intake and colorectal carci-
nomas harboring mutations in the key genes APC or BRAF
amongmen (40,41), indicating that folate may result in a growth
advantage of such tumors.
We observed that a relatively high intake of methioninemay be
inversely associated with proximal colon cancer in men and rectal
cancer in women. Previous studies examining the role of methi-
onine intake did not demonstrate an individual inverse association
with CRC risk (13,15–17), but 1 study showed that low methi-
onine combined with low folate and high alcohol intake may lead
to increased CRC risk (34). Although we did not observe an
interaction between folate and methionine, our findings suggest
that methionine, as a methyl donor, may be more effective in
preventing CRC than folate in some of the colorectal sublocaliza-
tions. There was also a weak inverse association between ribo-
flavin and proximal colon cancer in women only, whereas in men,
riboflavin was unrelated to CRC. Riboflavin is a cofactor for
MTHFR and a low intake of the vitamin may reduce the met-
abolic activity of this enzyme and thereby contribute to colorectal
carcinogenesis (8). In addition, the 677C . T polymorphism in
MTHFRmay also affect enzymatic activity and the occurrence of
this polymorphism was associated with reduced CRC risk among
subjects with adequate folate status (42). It is worthwhile to
further explore potential effect modification by such polymor-
phisms; however, as of today, this information is not yet available
for our cohort members.
The reason why an effect of methionine or riboflavin would
be site or gender specific remains unclear. Possibly, the develop-
ment of tumors harboring promoter hypermethylation, which
were observed more often in the proximal colon and among
women (41,43,44), is more sensitive to these nutrients. We do
not have information on global hypomethylation status; however,
it is unknown whether the level of global DNA hypomethylation
may differ between tumors in different sublocalizations of the
colorectum or between men and women.
A remarkable finding in our study was the strong positive
association between vitamin B-6 intake and rectal cancer in
women, with the RR strongly increased in the highest quintile of
intake. Also, when analyzing men and women and all colorectal
tumors combined, we observed a modest positive association
with the RR increasing evenly over quintiles of intake, sug-
gesting a linear dose-response effect. Meat intake appeared to be
the main contributor of vitamin B-6 intake (men, 23.8%;
women, 24.4%) and could therefore have accounted for the
positive association of vitamin B-6, because meat may also be a
risk factor for CRC. However, all analyses were adjusted for
meat intake. Interestingly, a positive association with rectal
cancer in women has previously been observed in the Iowa
women’s health population-based cohort study (16), whereas the
range of intake among women in that study was considerably
higher compared with our study. Notwithstanding this differ-
ence, these observations suggest that vitamin B-6 may indeed be
associated with increased CRC risk. Although these are obser-
vations based on subgroups of patients and thus caution should
be taken in interpreting such findings, these are 2 prospective
cohort studies showing a positive association between vitamin
B-6 and rectal cancer. Moreover, we previously observed that a
positive association between vitamin B-6 intake and CRC was
most pronounced among individuals with tumors harboring
human mut-L homolog 1 promoter hypermethylation (41). In
view of this finding, we hypothesize that a relatively high vita-
min B-6 intake may increase promoter hypermethylation and
thereby enhance the development of tumors with a methylation-
associated phenotype. However, because an inverse association
between vitamin B-6 and CRC has been suggested in a number
of previous prospective cohort studies (18–21), the role of
vitamin B-6 clearly needs further attention. In future research,
the role of vitamin B-6 in a hypermethylation-associated path-
way should be studied and preferably be investigated in even
larger cohort studies.
The current study was a population-based prospective cohort
design with a long follow-up period. The large number of
incident CRC patients is likely to have minimized the probability
of reporting results based on chance alone. It is also unlikely that
selection bias has occurred, because the follow-up of cases and
subcohort members was almost complete. Recall bias was
probably low, certainly if compared with retrospective case-
control designs, although measurement error is unavoidable
with self-administered FFQ and may still have biased results to
some extent. After a validation study, however, it was concluded
that the questionnaire is sufficiently able to rank subjects
according to dietary intake (24), suggesting reasonably adequate
validity of the single baseline measurement. Furthermore, poten-
tial preclinical disease is not likely to have affected exposure
status, because the results did not substantially change after
excluding the first year of follow-up.
This study could not account for potential changes in dietary
habits over time, because there have been no follow-up measure-
ments of dietary intake. We do nonetheless have information on
the reproducibility of the baseline FFQ, which was determined
from 5 annually repeated measurements in independent random
samples from the cohort. The average decline of the correlation
between follow-up measures was only minimal, indicating that
the ability of the baseline FFQ to rank subjects according to
dietary intake ismaintained relativelywell over a period of at least
5 y (25). Moreover, subjects aged 55–69 y at baseline and these
elderly people tend to have a more stable dietary habits compared
with younger individuals (22). Although follow-up was longer
than 5 y, for these reasons, we consider that potential changes in
dietary intake over time have presumably not influenced the
estimated associations to a great extent.
In conclusion, the current large prospective cohort study
suggests that dietary folate does not protect against CRC in this
Dutch population and that methionine may reduce CRC risk of
the proximal colon in men and rectum among women. Ribo-
flavin also tended to reduce the risk of proximal colon tumors in
women. Our study is the 2nd cohort study to show a positive
association between vitamin B-6 and rectal cancer among
women, which is interesting considering a possible similarity
with the recent insight in a potentially harmful effect of high
folate levels in colorectal carcinogenesis. However, we under-
score the need for larger studies or meta-analyses and to further
investigate the role of these nutrients in CRC development.
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